Better Therapeutics Inc. (BTTX)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

0.01

7300.00%

Pre-market Jun 20, 2024, 09:30 AM EDT

Company Description

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States.

Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.

The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels.

Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Better Therapeutics Inc.

Country	United States
IPO Date	Mar 17, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	54
CEO	Frank L. Karbe

Contact Details

Address: 548 Market Street San Francisco, California United States
Website	https://www.bettertx.com

Stock Details

Ticker Symbol	BTTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001832415
CUSIP Number	08773T104
ISIN Number	US08773T1043
Employer ID	00-0000000
SIC Code	8000

Key Executives

Name	Position
Frank L. Karbe	Chief Executive Officer, Interim Chief Financial Officer, President & Director
Andres Camacho	Senior Vice President of Technology & Head of Engineering
Angela Willis	Senior Vice President of Market Access
David P. Perry M.B.A.	Co-Founder & Executive Chairman
Dr. Mark A. Berman M.D.	Chief Medical Officer
Jessica Meng	Chief Commercial Officer
Kristin Wynholds	Chief Product Officer
Leslie Miller	Controller

Latest SEC Filings

Date	Type	Title
May 30, 2024	15-12G	Filing
May 23, 2024	POS AM	Filing
May 23, 2024	POS AM	Filing
May 23, 2024	POS AM	Filing
May 23, 2024	POS AM	Filing
May 23, 2024	POS AM	Filing
May 23, 2024	S-8 POS	Filing
May 23, 2024	S-8 POS	Filing
May 16, 2024	25-NSE	Filing
Mar 21, 2024	424B3	Filing

View All SEC Filings